JP5132869B2 - 2−18f−フルオロ−2−デオキシ−d−グルコース(18f−fdg)−溶液を得るための方法 - Google Patents
2−18f−フルオロ−2−デオキシ−d−グルコース(18f−fdg)−溶液を得るための方法 Download PDFInfo
- Publication number
- JP5132869B2 JP5132869B2 JP2003587417A JP2003587417A JP5132869B2 JP 5132869 B2 JP5132869 B2 JP 5132869B2 JP 2003587417 A JP2003587417 A JP 2003587417A JP 2003587417 A JP2003587417 A JP 2003587417A JP 5132869 B2 JP5132869 B2 JP 5132869B2
- Authority
- JP
- Japan
- Prior art keywords
- fdg
- solution
- glucose
- deoxy
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/001—Acyclic or carbocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B63/00—Purification; Separation; Stabilisation; Use of additives
- C07B63/04—Use of additives
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
a)18F−フルオロ−デオキシ−グルコース(18F−FDG)−溶液を用意すること、および、
b)弱酸をベースとする少なくとも1種の緩衝剤を18F−FDG−溶液に添加すること。
弱酸緩衝剤は、生理的に許容し得るものであるべきであり、好ましくは、クエン酸塩緩衝剤、酢酸塩緩衝剤、アスコルビン酸塩緩衝剤またはこれらの緩衝剤の組合せである。
実施例1
pH範囲4.5ないし5.5での 18 F−FDG−溶液のオートクレーブ処理
本実施例では、塩水中の非緩衝溶液と比較して、弱酸で緩衝された18F−フルオロ−デオキシ−グルコース(FDG)−溶液の放射化学的純度を研究するために、3回の試験を実施した。
表1は、様々に緩衝された18F−フルオロ−デオキシ−グルコース(FDG)−溶液の、134℃で5分間オートクレーブ処理した後の放射化学的純度を示す。測定は、オートクレーブ処理後すぐに、KAVO SterimasterTM を使用して実行した。
本実施例では、弱酸でpH2−3に緩衝された18F−フルオロ−デオキシ−グルコース(FDG)−溶液の放射化学的純度を研究するために、2回の試験を実施した。
表2は、様々に緩衝された18F−フルオロ−デオキシ−グルコース(FDG)−溶液の、134℃で5分間オートクレーブ処理した後の放射化学的純度を示す。
18 F−FDGの放射線分解
18F−FDGの放射線分解を約8.5時間にわたり測定した。放射能濃度は、ART(t=0)で3mCi/mlであった。
2つの緩衝剤を試験し、0.9%NaCl/pH6.9中の参照サンプルと比較した。第1の緩衝剤は、クエン酸塩緩衝剤pH4.5であり、第2の緩衝剤は、アスコルビン酸塩緩衝剤pH4.5であった。期間中に、サンプルの放射化学的純度の測定を5回実行した。結果を表3に示す。
18 F−フルオロ−デオキシ−グルコース(FDG)−溶液のオートクレーブ処理と放射線分解
サンプルをオートクレーブ処理した後、18F−FDGの放射線分解を約7.5時間にわたり測定した。2つの緩衝剤を試験し、0.9%NaCl/pH6.9中の参照サンプルと比較した。第1は、クエン酸塩緩衝剤pH4.5であり、第2は、アスコルビン酸塩緩衝剤pH4.5であった。期間中に、サンプルの放射化学的純度の測定を3回実行した。結果を表4に示す。
Claims (4)
- 18F−フルオロ−デオキシ−グルコース(18F−FDG)−溶液のオートクレーブ処理される能力を改良し、これにより該溶液を医学的適用に適合させる方法であって、該方法は、
a)18F−フルオロ−デオキシ−グルコース(18F−FDG)−溶液を用意すること、および、
b)弱酸をベースとする少なくとも1種の緩衝剤を18F−フルオロ−デオキシ−グルコース(18F−FDG)−溶液に添加すること、
の各段階を含み、該弱酸をベースとする緩衝剤が、クエン酸塩、酢酸塩、アスコルビン酸塩およびこれらの組合せからなる群から選択され
該クエン酸塩緩衝剤のpHが5.5より低く、
該酢酸塩緩衝剤のpHが3.0ないし5.5であり、
該アスコルビン酸塩緩衝剤のpHが3.0ないし5.5である、
、方法。 - 前記改良が、18F−フルオロ−デオキシ−グルコース(18F−FDG)−溶液の放射線分解の低減である、請求項1に記載の方法。
- クエン酸塩緩衝剤のpHが2ないし5.5である、請求項1に記載の方法。
- 請求項1の方法によって得られる、物理的/化学的特徴が改良された18F−フルオロ−デオキシ−グルコース(18F−FDG)−溶液。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02076638A EP1356827A1 (en) | 2002-04-24 | 2002-04-24 | Method for obtaining a 2-18F-fluor-2-deoxy-D-glucose (18F-FDG)-solution |
EP02076638.2 | 2002-04-24 | ||
PCT/US2003/012603 WO2003090789A1 (en) | 2002-04-24 | 2003-04-23 | Method for obtaining a 2-18f-fluor-2-deoxy-d-glucose (18f-fdg) - solution |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010171216A Division JP2010248244A (ja) | 2002-04-24 | 2010-07-29 | 2−18f−フルオロ−2−デオキシ−d−グルコース(18f−fdg)−溶液を得るための方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006500319A JP2006500319A (ja) | 2006-01-05 |
JP5132869B2 true JP5132869B2 (ja) | 2013-01-30 |
Family
ID=28685968
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003587417A Expired - Lifetime JP5132869B2 (ja) | 2002-04-24 | 2003-04-23 | 2−18f−フルオロ−2−デオキシ−d−グルコース(18f−fdg)−溶液を得るための方法 |
JP2010171216A Pending JP2010248244A (ja) | 2002-04-24 | 2010-07-29 | 2−18f−フルオロ−2−デオキシ−d−グルコース(18f−fdg)−溶液を得るための方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010171216A Pending JP2010248244A (ja) | 2002-04-24 | 2010-07-29 | 2−18f−フルオロ−2−デオキシ−d−グルコース(18f−fdg)−溶液を得るための方法 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8182788B2 (ja) |
EP (2) | EP1356827A1 (ja) |
JP (2) | JP5132869B2 (ja) |
KR (1) | KR20050005456A (ja) |
CN (1) | CN1323724C (ja) |
AT (1) | ATE422903T1 (ja) |
AU (1) | AU2003225124B2 (ja) |
CA (1) | CA2483181C (ja) |
DE (1) | DE60326220D1 (ja) |
IL (2) | IL164805A0 (ja) |
NO (1) | NO329160B1 (ja) |
PL (1) | PL371682A1 (ja) |
WO (1) | WO2003090789A1 (ja) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0422004D0 (en) * | 2004-10-05 | 2004-11-03 | Amersham Plc | Method of deprotection |
US20080193379A1 (en) * | 2005-06-14 | 2008-08-14 | Nihon Medi-Physics Co., Ltd. | Radioactive Diagnostic Imaging Agent |
TW200803903A (en) * | 2006-04-28 | 2008-01-16 | Nihon Mediphysics Co Ltd | Novel compound having affinity to amyloid |
KR20090025282A (ko) * | 2006-06-21 | 2009-03-10 | 니혼 메디피직스 가부시키가이샤 | 신규 아밀로이드 친화성 화합물 |
EP2029182A2 (en) | 2006-06-21 | 2009-03-04 | GE Healthcare AS | Stabilisation of radiopharmaceutical precursors |
JPWO2008056481A1 (ja) * | 2006-11-09 | 2010-02-25 | 日本メジフィジックス株式会社 | 放射性画像診断剤 |
RU2445120C2 (ru) | 2006-12-21 | 2012-03-20 | Нихон Меди-Физикс Ко., Лтд. | Радиоактивный агент для диагностической визуализации |
US8343459B2 (en) | 2007-02-13 | 2013-01-01 | Nihon Medi-Physics Co., Ltd. | Method for production of radiation diagnostic imaging agent |
TW200918102A (en) * | 2007-10-24 | 2009-05-01 | Nihon Mediphysics Co Ltd | Novel compound having affinity for amyloid |
CA2704172A1 (en) * | 2007-10-30 | 2009-05-07 | Nihon Medi-Physics Co., Ltd. | Use of novel compound having affinity for amyloid, and process for production of the same |
JPWO2009057577A1 (ja) * | 2007-10-30 | 2011-03-10 | 日本メジフィジックス株式会社 | 新規アミロイド親和性化合物の使用及び製造方法 |
EP2214722A1 (en) * | 2007-11-07 | 2010-08-11 | GE Healthcare BV | Stabilization of radiopharmaceuticals |
EP2419096B1 (en) | 2009-04-15 | 2019-11-13 | Lantheus Medical Imaging, Inc. | Stabilization of radiopharmaceutical compositions using ascorbic acid |
WO2012021882A2 (en) * | 2010-08-13 | 2012-02-16 | Siemens Medical Solutions Usa, Inc. | Formulation, apparatus and method for stabilizing radiopharmaceuticals |
DK2658831T3 (en) | 2010-12-29 | 2017-04-24 | Ge Healthcare Ltd | elution |
US20130005958A1 (en) * | 2011-06-30 | 2013-01-03 | General Electric Company | Devices and methods for reducing radiolysis of radioisotopes |
US20130004414A1 (en) * | 2011-06-30 | 2013-01-03 | General Electric Company | Devices and methods for reducing radiolysis of radioisotopes |
US20150231249A1 (en) * | 2011-12-21 | 2015-08-20 | Ge Healthcare Limited | 18f-fluciclovine compositions in citrate buffers |
US11534494B2 (en) | 2011-12-21 | 2022-12-27 | Ge Healthcare Limited | Formulation and method of synthesis |
GB201411569D0 (en) | 2014-06-30 | 2014-08-13 | Ge Healthcare Ltd | Novel formulation and method of synthesis |
GB201202420D0 (en) * | 2012-02-13 | 2012-03-28 | Ge Healthcare Ltd | Radiotracer compositions |
FR3054445B1 (fr) * | 2016-07-26 | 2019-07-05 | Laboratoires Cyclopharma | Synthese d'une composition d'agent radioactif |
US10695450B2 (en) | 2016-07-26 | 2020-06-30 | Laboratoires Cyclopharma | Synthesis of a radioactive agent composition |
GB202005282D0 (en) * | 2020-04-09 | 2020-05-27 | Blue Earth Diagnostics Ltd | Pharmaceutical Formulations |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4707353A (en) * | 1982-12-08 | 1987-11-17 | Mallinckrodt, Inc. | Radiographic imaging agents |
SE9002117L (sv) * | 1990-06-14 | 1991-08-26 | Nils Elander | Mikrovaagsanordning foer behandling av precessvaetskor |
JP3370666B2 (ja) | 1990-07-06 | 2003-01-27 | マリンクロッド・インコーポレイテッド | 放射性レニウム錯体溶液の調製法 |
JPH0797340A (ja) * | 1993-06-03 | 1995-04-11 | Terumo Corp | Mri造影剤組成物 |
BE1010280A3 (fr) * | 1996-05-02 | 1998-05-05 | Coincidence S A | Procede et dispositif de synthese de 2-[18f] fluoro-2-deoxy-d-glucose. |
AU736481C (en) * | 1996-10-07 | 2002-06-06 | Du Pont Pharmaceuticals Company | Radiopharmaceuticals for imaging infection and inflammation |
-
2002
- 2002-04-24 EP EP02076638A patent/EP1356827A1/en not_active Withdrawn
-
2003
- 2003-04-23 DE DE60326220T patent/DE60326220D1/de not_active Expired - Lifetime
- 2003-04-23 EP EP03721834A patent/EP1496946B1/en not_active Expired - Lifetime
- 2003-04-23 KR KR10-2004-7016968A patent/KR20050005456A/ko active IP Right Grant
- 2003-04-23 JP JP2003587417A patent/JP5132869B2/ja not_active Expired - Lifetime
- 2003-04-23 CA CA2483181A patent/CA2483181C/en not_active Expired - Lifetime
- 2003-04-23 US US10/510,454 patent/US8182788B2/en active Active
- 2003-04-23 AU AU2003225124A patent/AU2003225124B2/en not_active Ceased
- 2003-04-23 IL IL16480503A patent/IL164805A0/xx unknown
- 2003-04-23 AT AT03721834T patent/ATE422903T1/de not_active IP Right Cessation
- 2003-04-23 PL PL03371682A patent/PL371682A1/xx not_active IP Right Cessation
- 2003-04-23 WO PCT/US2003/012603 patent/WO2003090789A1/en active Search and Examination
- 2003-04-23 CN CNB03809035XA patent/CN1323724C/zh not_active Expired - Fee Related
-
2004
- 2004-10-25 IL IL164805A patent/IL164805A/en active IP Right Grant
- 2004-11-22 NO NO20045070A patent/NO329160B1/no not_active IP Right Cessation
-
2010
- 2010-07-29 JP JP2010171216A patent/JP2010248244A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2003090789A1 (en) | 2003-11-06 |
EP1496946B1 (en) | 2009-02-18 |
US8182788B2 (en) | 2012-05-22 |
EP1356827A1 (en) | 2003-10-29 |
AU2003225124A1 (en) | 2003-11-10 |
PL371682A1 (en) | 2005-06-27 |
US20050175536A1 (en) | 2005-08-11 |
JP2006500319A (ja) | 2006-01-05 |
EP1496946A1 (en) | 2005-01-19 |
KR20050005456A (ko) | 2005-01-13 |
JP2010248244A (ja) | 2010-11-04 |
IL164805A0 (en) | 2005-12-18 |
DE60326220D1 (de) | 2009-04-02 |
CA2483181C (en) | 2011-06-28 |
CN1323724C (zh) | 2007-07-04 |
ATE422903T1 (de) | 2009-03-15 |
NO20045070L (no) | 2004-11-22 |
NO329160B1 (no) | 2010-08-30 |
CA2483181A1 (en) | 2003-11-06 |
AU2003225124B2 (en) | 2007-06-14 |
IL164805A (en) | 2009-06-15 |
CN1646175A (zh) | 2005-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5132869B2 (ja) | 2−18f−フルオロ−2−デオキシ−d−グルコース(18f−fdg)−溶液を得るための方法 | |
RU2474435C2 (ru) | Стабилизация радиофармацевтических композиций | |
CN107261159B (zh) | 使用抗坏血酸稳定化放射性药物组合物 | |
Li et al. | Translating the concept of peptide labeling with 5-deoxy-5-[18 F] fluororibose into preclinical practice: 18 F-labeling of Siglec-9 peptide for PET imaging of inflammation | |
JP2023126209A (ja) | 安定な濃厚放射性核種錯体溶液 | |
JP5774023B2 (ja) | 疎水性pet剤を用いたpetイメージングのために適した配合物 | |
US4071613A (en) | Stabilized alcohol solution of reducing salt formulations for use in preparing radioisotope labeled scanning agents: liver scanning technetium-99m colloid and method of preparation | |
US11840592B2 (en) | Preparations of meta-iodobenzylguanidine and precursors thereof | |
US4298591A (en) | Instantaneous radioiodination of rose bengal at room temperature and a cold kit therefor | |
WO2023083209A1 (zh) | 一种靶向psma抗原的配体化合物及其螯合物与用于前列腺癌诊断和治疗的应用 | |
JP6787781B2 (ja) | 高純度治療用骨剤 | |
JP4649084B2 (ja) | テクネチウムTc99mテボロキシム心筋灌流剤の調製のためのキット | |
CN114685389B (zh) | 一种基于迈克尔加成的pet显像剂、制备方法与用途 | |
AU2016297308A9 (en) | Composition for stabilizing radiochemical purity of [18F]fluoro-dopa and method for preparing same | |
JPS5842846B2 (ja) | 肝臓および骨髄走査用テクネチウム−99m標識放射線診断剤とその製造法 | |
JP5105343B2 (ja) | 局所脳血流診断用放射性医薬品 | |
US20200129646A1 (en) | Radioactive labeled long-acting peptide targeted pharmaceutical and production method thereof | |
CN116920128A (zh) | 一种放射性药物水溶液及其用途 | |
Varlamova et al. | Synthesis and Study of Norfloxacin Labeled with Technecium-99m as a Potential Imaging Agent of Bacterial Inflammations | |
CN116920129A (zh) | 放射性药物水溶液及其制备方法和用途 | |
FR2554348A1 (fr) | Complexes hepariniques marques au moyen de radio-elements de vie courte emetteurs de radiations non ionisantes, leur procede d'obtention, les produits intermediaires et application de ces complexes | |
Ogan et al. | Preparation of [125I]‐3H2‐iopiperidol‐A by exchange radioiodination | |
EP2000154A9 (en) | Composition for preparation of radioactive pharmaceutical for diagnosis of regional cerebral blood flow | |
CS201754B1 (cs) | Způsob výroby injekčního roztoku bengálské'červeně značené radioaktivním izotopem jódu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060418 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080530 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080617 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080617 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100223 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100330 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100729 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100813 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100910 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120130 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120202 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120228 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120302 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121107 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151116 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5132869 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151116 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R360 | Written notification for declining of transfer of rights |
Free format text: JAPANESE INTERMEDIATE CODE: R360 |
|
R371 | Transfer withdrawn |
Free format text: JAPANESE INTERMEDIATE CODE: R371 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |